Retigabine - Bausch Health Companies/GlaxoSmithKline

Drug Profile

Retigabine - Bausch Health Companies/GlaxoSmithKline

Alternative Names: ADD-230001; AW21-360; D-20443; D-20443 dihydrochloride; D-23129; Ezogabine; Ezogabine-XR; GKE 841; GW-582892X; Potiga; Retigabine-XR; Trobalt; WAY-143841

Latest Information Update: 17 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meda
  • Developer Bausch Health Companies; GlaxoSmithKline; Harvard University; Massachusetts General Hospital; The ALS Association; Valeant Pharmaceuticals International
  • Class Antiepileptic drugs; Carbamates; Fluorobenzenes; Phenylenediamines; Small molecules
  • Mechanism of Action GABA A receptor agonists; KCNQ potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Partial epilepsies
  • Discontinued Amyotrophic lateral sclerosis; Lennox-Gastaut syndrome; Postherpetic neuralgia

Most Recent Events

  • 17 Jul 2018 GlaxoSmithKline terminates a phase III extension trial in Partial seizures (Adjunctive treatment) in Australia, France, Israel, Poland, Ukraine, Russia, South Africa, United Kingdom, Hungary, Belgium, Spain and Germany as there was no longer any benefit in collecting data since retigabine had been withdrawn from market (PO) (NCT00310388)
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top